On August 11, PHARMARON rose 3.06% in regular trading, trading at 28.22 HKD/share, with turnover of 64.65 million HKD. The rally was driven by continued strength across the CXO sector and the approaching board meeting scheduled for August 20 to review H1 interim results.

The company previously guided H1 revenue of 7.47 billion to 7.67 billion yuan, representing 16%-19% year-over-year growth, with net profit growth of 4%-10%. Notably, newly signed orders surged over 30% in H1, with small-molecule CDMO new orders growing over 50%, reflecting robust demand recovery. Industry leader WuXi AppTec reported H1 revenue growth of 38.93% and net profit growth of 29.43%, reinforcing sector-wide momentum and valuation recovery.

Within the Life Sciences Tools and Services sector, peers also advanced: WuXi AppTec rose 1.62%, WuXi Biologics gained 2.52%, GenScript Biotech climbed 2.90%, and XtalPi added 4.24%. JPMorgan increased its stake by approximately 1.29 million shares in July at 22.11 HKD per share, bringing its holding to 7.32%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)